Adult vaccines are vaccines that are recommended for adults aged 19 years and older to provide immunity against potentially life-threatening diseases like pneumonia, meningitis, shingles, and tetanus. Adult vaccines help protect individuals from infectious diseases throughout their lifespan. As people age, their immune systems weaken, placing them at higher risk of developing severe complications from vaccine-preventable diseases. Vaccines are one of the most effective and cost-efficient public health tools available for disease prevention. The global adult vaccines market offers products like pneumococcal vaccine, influenza vaccine, meningococcal vaccine, zoster vaccine, diphtheria, tetanus, and pertussis vaccine, measles, mumps, and rubella vaccine, and others that help protect adults from more fatal illnesses. The global adult vaccines market is estimated to be valued at US$ 16,790.11 Mn in 2023 and is expected to exhibit a CAGR of 7.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Opportunity:

The opportunity to prevent life-threatening diseases will drive the growth of the adult vaccines market. As adults age, they become more susceptible to serious diseases like pneumonia, meningitis, hepatitis, and shingles. According to the World Health Organization (WHO), pneumonia caused 2.5 million deaths globally in 2019, making it the leading cause of death among infectious diseases. Meningitis also poses a significant threat, with an estimated 370,000 cases reported every year in the U.S., Europe, and Australia. Immunization through adult vaccines offers protection against these lethal diseases. They bolster immunity and reduce the risk of illness, hospitalization, long-term complications, and mortality. The availability of effective vaccines to safeguard against high-impact infectious diseases of adulthood will continue creating lucrative prospects in the market over the forecast period.

Porter’s Analysis
Threat of new entrants: The adult vaccine market requires substantial investment for R&D and production facilities, reducing threat of new entrants. Regulations around clinical trials also increase barriers.

Bargaining power of buyers: There are many vaccine manufacturers for common diseases like influenza. This gives buyers bargaining power to negotiate on price and quality.

Bargaining power of suppliers: Key raw materials and technology providers have some bargaining power due to specialized expertise and access. Overall bargaining power of suppliers is moderate.

Threat of new substitutes: There are no close substitutes for vaccines in preventing infectious diseases. Threat of new substitutes is low.

Competitive rivalry: The market has large players with broad product portfolios competing on innovation, prices and marketing. Intense competition prevails.

SWOT Analysis
Strength: Established brands and partnerships increase customer trust. Funding for R&D leads to new product launches.

Weakness: High capital requirements and stringent regulations increase business risks and costs. Vaccine hesitancy impacts demand.

Opportunity: Increasing healthcare spending in emerging nations boosts access. Growing elderly population drives preventive healthcare needs.

Threats: Price controls and public procurement policies impact profitability. Outbreaks of new diseases requires rapid vaccine development.

Key Takeaways
The global adult vaccines market is expected to witness high growth.

Regional Analysis: North America currently dominates due to supportive vaccination policies and affordable healthcare systems boosting demand. However, Asia Pacific is likely to see rapid gains due to rising incomes, expansion of healthcare infrastructure and government immunization programs in populous nations like India and China.

Key players operating in the adult vaccines market are GlaxoSmithKline Plc, Merck & Co., Sanofi Pasteur, Pfizer Inc., CSL Limited, Johnson & Johnson, Serum Institute of India, Medimmune, and AstraZeneca Plc. Leading companies are expanding manufacturing capacities and collaborating with regional players to strengthen distribution networks. Innovation in vaccine formulations, expanded disease cover and life-cycle management also remain high priorities.